1. Home
  2. TBPH vs GNE Comparison

TBPH vs GNE Comparison

Compare TBPH & GNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TBPH
  • GNE
  • Stock Information
  • Founded
  • TBPH 2013
  • GNE 2011
  • Country
  • TBPH United States
  • GNE United States
  • Employees
  • TBPH N/A
  • GNE N/A
  • Industry
  • TBPH Biotechnology: Pharmaceutical Preparations
  • GNE Power Generation
  • Sector
  • TBPH Health Care
  • GNE Utilities
  • Exchange
  • TBPH Nasdaq
  • GNE Nasdaq
  • Market Cap
  • TBPH 464.5M
  • GNE 402.0M
  • IPO Year
  • TBPH N/A
  • GNE N/A
  • Fundamental
  • Price
  • TBPH $10.77
  • GNE $22.62
  • Analyst Decision
  • TBPH Buy
  • GNE
  • Analyst Count
  • TBPH 3
  • GNE 0
  • Target Price
  • TBPH $11.33
  • GNE N/A
  • AVG Volume (30 Days)
  • TBPH 379.4K
  • GNE 161.9K
  • Earning Date
  • TBPH 05-08-2025
  • GNE 05-06-2025
  • Dividend Yield
  • TBPH N/A
  • GNE 1.32%
  • EPS Growth
  • TBPH N/A
  • GNE 10.33
  • EPS
  • TBPH N/A
  • GNE 0.55
  • Revenue
  • TBPH $65,266,000.00
  • GNE $442,321,000.00
  • Revenue This Year
  • TBPH $51.09
  • GNE N/A
  • Revenue Next Year
  • TBPH N/A
  • GNE N/A
  • P/E Ratio
  • TBPH N/A
  • GNE $41.02
  • Revenue Growth
  • TBPH 6.11
  • GNE N/A
  • 52 Week Low
  • TBPH $7.44
  • GNE $13.05
  • 52 Week High
  • TBPH $11.82
  • GNE $22.71
  • Technical
  • Relative Strength Index (RSI)
  • TBPH 64.32
  • GNE 84.83
  • Support Level
  • TBPH $9.10
  • GNE $18.38
  • Resistance Level
  • TBPH $11.82
  • GNE $21.90
  • Average True Range (ATR)
  • TBPH 0.39
  • GNE 0.93
  • MACD
  • TBPH 0.19
  • GNE 0.22
  • Stochastic Oscillator
  • TBPH 62.23
  • GNE 97.46

About TBPH Theravance Biopharma Inc.

Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to better meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

About GNE Genie Energy Ltd. Class B Stock

Genie Energy Ltd, through its subsidiaries, operates as a retail energy provider. It serves two reportable business segments: Genie retail energy, or GRE, and Genie renewables. The Genie retail energy segment resells energy to residential and commercial consumers in the Eastern and Midwestern United States through its portfolio of various retail energy providers. The Genie renewables segment holds controlling interests in various companies engaged in the manufacturing of solar panels, solar installation design, and solar energy project management. It generates the majority of its revenue from the Genie retail energy segment.

Share on Social Networks: